Home
 
Sitemap
 
Legal Statement
 
 
 
 
 
 
 
 
 
Home > Company > People > Board of Directors > Nominating & Governance Committee
 
Company
 
 
 
 
 
 
 
 
 
 
 
Facts and Figures
 
 
 
Company Strategy
 
 
 
Partnerships
 
 
People
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Compensation Committee
 
 
Finance & Audit Committee
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Milestones
 
 
 
Annual Reports
 
 
 
Actelion worldwide
 
 
 
Contact
 
 
 
Nomination & Governance Commitee


Robert Cawthorn - Chairman of the Nominating & Governance Committee
Robert E. Cawthorn is an investor in Actelion and Chairman of the Board of Directors. Robert Cawthorn has a unique and successful track record of over 35 years in the pharmaceutical industry, which includes establishing start-ups and managing large pharmaceutical companies. Following his retirement as Chairman and CEO of Rhô-Poulenc-Rorer, Inc., he was a managing director of Global Health Care Partners, DLJ Merchant Banking. After 17 years as an executive with Pfizer International, he became the first president of Biogen and was active in creating the foundations for the future success of the company. He joined the Rorer Group in 1982 and, as Chairman and CEO, led the transformation of Rorer from a small, primarily over-the-counter pharmaceutical company into a major research-driven company, culminating in the merger that created Rhône-Poulenc-Rorer.

Andre Mueller - Vice Chairman of the Board of Directors
With two degrees in Chemical Engineering and Business Administration from INSEAD, André Mueller started his career with CIBA Ltd and Sandoz (now Novartis) where he held a number of managerial positions in the strategic planning and finance divisions both at headquarters and in the US. After seven years with Sandoz, he moved to Biogen, becoming VP of Finance and Administration and then CFO. As CFO he was responsible for several financing rounds including Biogen's IPO. Four years later, he became a Founding Partner and Director of Investments for Genevest, the first Swiss venture capital organization.

Armin Kessler  - Armin M. Kessler served as Chief Operating Officer of Hoffmann-La Roche in Basel Switzerland from 1990 to 1995. Prior to being appointed COO, he held several senior positions at Hoffmann-La Roche, including head of the pharmaceutical and diagnostic divisions of the organization. Earlier positions in his career included Director of Pharmaceutical Marketing Worldwide for Sandoz (now Novartis) and President of Sandoz KK in Tokyo. He currently serves on the board of The Medicines Company, Gen_Probe and Spectrum Pharmaceuticals (formerly Neotherapeutics) and has served on the boards of Hoffmann-La Roche, Syntex and Genentech. He received a degree in Physics and Chemistry from Pretoria University in South Africa, a degree in Chemical Engineering from the University of Cape Town, South Africa, a Juris Doctorate from Seton Hall University, New Jersey, and Dr. h.c. in Business Administration from the University of Pretoria.

Carl Feldbaum - Carl B. Feldbaum was president of the Biotechnology Industry Organization (BIO) in Washington, D.C. from its founding in 1993 to January 2005. Earlier roles concluded president and founder of the Palomar Corporation, a national security "think tank" in Washington, D.C.. He also served as assistant to the Secretary of Energy and as the Inspector General for defense intelligence in the U.S. Department of Defense. In 1979, he was awarded the Distinguished Civilian Service Medal from Defense Secretary Harold Brown. After receiving a bachelor's degree in Biology from Princeton University and a law degree from the University of Pennsylvania Law School, Mr. Feldbaum came to Washington D.C. in 1973 as an assistant special prosecutor for the Watergate special prosecution force.


Last update: 03 Mar 2005

 
 
 
 

Charter Nominating & Governance Committee